Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 251-256

  Yip, Yvonne ^a   Victor, Frantz ^a   Lamar, Jason ^a   Johnson, Robert ^a   Wang, Q May ^a   Barket, Donna ^a   Glass, John ^a   Jin, Ling ^a   Liu, Lifei ^a   Venable, Daryl ^a   Wakulchik, Mark ^a   Xie, Congping ^a   Heinz, Beverly ^a   Villarreal, Elcira ^a   Colacino, Joe ^a   Yumibe, Nathan ^a   Tebbe, Mark ^a   Munroe, John ^a   Chen, Shu Hui ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LY 514962; PROLINE DERIVATIVE; PROTEINASE INHIBITOR;

ARTICLE; CELL ACTIVITY; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; RAT; REACTION ANALYSIS; REPLICON;

HEPATITIS C VIRUS;

EID: 0347517809     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.074     Document Type: Article

References (33)

1. Dymock B.W., Emerging Drugs, 2001, 6, 13.
2. Dymock B.W., Jones P.S., Wilson F.X., Antiviral Chem. Chemother., 2000, 11, 79.
3. (a) For recent reviews, see: Dymock B.W. Emerging Drugs. 6:2001;13 (b) Dymock B.W., Jones P.S., Wilson F.X. Antiviral Chem. Chemother. 11:2000;79 (c) Clarke B. J. Gen. Virol. 78:1997;2397.
4. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.-H., Cort S., Albrecht J.K. New Engl. J. Med. 339:1998;1485.
5. Zeuzem S., Feinman V., Rasenack J., Heathcote E.J., Lai M.-Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M.J. New Engl. J. Med. 343:2000;1666.
6. Heathcote E.J., Shiffman M.L., Cooksley W.G.E., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., De Pamphilis J. New Engl. J. Med. 343:2000;1673.
7. For an overview of HCV, see: Bartenschlagar R. Antiviral Chem. Chemother. 8:1997;281.
8. Kwong A.D., Kim J.L., Rao G., Lipovsek D., Raybuck S.A. Antiviral Res. 40:1998;1.
9. (a) Peptidyl aldehydes: Tung, R.; Harbeson, S. L.; Deininger, D. D.; Murcko, M. A.; Bhisetti, G. R.; Farmer, L. J. PCT Patent (Vertex) WO/98/17679, 10/18/1996.
10. (b) PCT Patent (Vertex): WO/99/50230, 3/31/1998. (c) Perni R.B., Britt S.D., Court J.C., Courtney L.F., Deininger D.D., Farmer L.J., Gates C.A., Harbeson S.L., Kim J.L., Landro J.A., Levin R.B., Luong Y.-P., O'Malley E.T., Pitlik J., Rao G., Schairer W.C., Thomson J.A., Tung R.D., Van Drie J.H., Wei Y. Bioorg. Med. Chem. 13:2003;4059.
11. Attwood M.R., Bennett J.M., Campbell A.D., Canning G.G.M., Carr M.G., Conway E., Dunsdon R.M., Greening J.R., Jones P.S., Kay P.B., Handa B.K., Hurst D.N., Jennings N.S., Jordan S., Keech E., O'Brien M.A., Overton H.A., King-Underwood J., Raynham T.M., Stenson K.P., Wilkinson C.S., Wilkinson T.C.I., Wilson F.X., Antiviral Chem. Chemother., 1999, 10, 259.
12. (a) Boronic acids: Attwood M.R., Bennett J.M., Campbell A.D., Canning G.G.M., Carr M.G., Conway E., Dunsdon R.M., Greening J.R., Jones P.S., Kay P.B., Handa B.K., Hurst D.N., Jennings N.S., Jordan S., Keech E., O'Brien M.A., Overton H.A., King-Underwood J., Raynham T.M., Stenson K.P., Wilkinson C.S., Wilkinson T.C.I., Wilson F.X. Antiviral Chem. Chemother. 10:1999;259. and references cited therein (b) Priestley E.S., Decicco C.P. Org. Lett. 2:2000;3095.
13. Phosphonates: PCT Patent (BI): WO/99/07734, 11/8/1997.
14. Peptidyl acids: (1) PCT Patent (BI): WO/99/07733, 11/08/1997.
15. (b) PCT Patent (BI): WO/00/09543, 10/8/1998.
16. (c) Poupart M.-A., Cameron D.R., Chabot C., Ghiro E., Goudreau N., Goulet S., Poirier M., Tsantrizos Y.S. J. Org. Chem. 66:2001;4743.
17. α-Ketoacids: PCT Patent: WO/99/64442, 10/6/1998.
18. (a) α-Ketoamides: Bennett J.M., Campbell A.D., Campbell A.J., Carr M.G., Dunsdon R.M., Greening J.R., Hurst D.N., Jennings N.S., Jones P.S., Jordan S., Kay P.B., O'Brien M.A., King-Underwood J., Raynham T.M., Wilkinson C.S., Wilkinson T.C.I., Wilson F.X. Bioorg. Med. Chem. Lett. 11:2001;355
19. (b) Han W., Hu Z., Jiang X., Decicco C.P. Bioorg. Med. Chem. Lett. 10:2000;711
20. (c) PCT Patent (BI): WO/99/07733, 11/8/1997.
21. (d) Tung, R.; Harbeson, S. L.; Deininger, D. D.; Murcko, M. A.; Bhisetti, G. R.; Farmer, L. J. US Patent (Vertex): 6,265,380 B1, 7/24/2001.
22. PCT Patent (Eli Lilly): WO/02/18369 A2, Mar. 7, 2002.
23. Prime site inhibitors: Ingallinella P., Fattori D., Altamura S., Steinkuler C., Koch U., Cirero D., Bazzo R., Cortese R., Bianchi E., Pessi A. Biochemistry. 41:2002;5483.
24. HOAT/DCC(DIC) was used to minimize racemization occurred at α-carbon during peptide coupling; cf.: Carpino L.A., El-Faham A. Tetrahedron. 55:1999;6813.
25. For the synthesis of racemic form of compound II, see: Monn J.A., Valli M.J. J. Org. Chem. 59:1994;2773. The enantiomerically pure version of compound II was obtained via chiral HPLC separation.
26. P1-Nva α-hydroxyacid was prepared from Z-Val(H) via its corresponding cyanohydrin intermediate.
27. Barton D.H.R., McCombie S.W. J. Chem. Soc., Perkin Trans. 1. 1975;1574.
28. i values were calculated from rate versus (inhibitor) plots, at fixed concentrations of enzyme and substrate, by a nonlinear least squares fit of the data to the equation of Morrison for tight binding competitive inhibition: Morrison, J. F. Biochim. Biophys. Acta 1969, 185, 269. The Prism program (GraphPad Software) was used for this procedure.
29. A panel of 10 human serine and cysteine proteases including elastase, chymotrypsin, trypsin, kallikrein, plasmin, thrombin, Factor Xa, and cathepsins B, G, and L were selected. Assays were performed using the conditions substrates suggested by the manufacturer.
30. Lohmann V., Korner F., Koch J.-O., Herian U., Theilmann L., Bartenschlager R., Science, 1999, 285, 110.
31. (a) Replicon assay: Lohmann V., Korner F., Koch J.-O., Herian U., Theilmann L., Bartenschlager R. Science. 285:1999;110 (b) Blight K., Kolykhalov A., Rice C. Science. 290:2000;1972.
32. XTT cytotoxicity assay: Roehm N.W., Rodgers G.H., Hatfield S.M., Glasebrook A.L. J. Immunol. Methods. 142:1991;257.
33. Four-step sequence overall yields for 4a: 51%; 4b: 70%; 5a: 65%; 5b: 71%; 5c: 52%; 6a: 51%; 6b: 59%; 6c: 20%; 6d: 31%; 7b: 44%; 7c: 23%; 7d: 32%; 8a: 42%; 8c: 44%.